Yokukansan (TJ-54) for treatment of very-late-onset schizophrenia-like psychosis: An open-label study

Miyaoka, Tsuyoshi; Wake, Rei; Furuya, Motohide; Liaury, Kristian; Ieda, Masa; Kimura, Kazunori; Tsuchie, Keiko; Fukushima, Michiyo; Ishihara, Kotomi; Araki, Toshimitsu; Hashioka, Sadayuki; Horiguchi, Jun

doi:10.1016/j.phymed.2013.01.007

Cited by 18 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four weeks of adjunctive therapy with YKS for treatment-resistant schizophrenia has been found to decrease Positive and Negative Syndrome Scale scores on the schizophrenia subscale without changing Drug-Induced Extrapyramidal Symptom Scale total scores 19. Similarly, 4 weeks of adjunctive therapy with YKS for very late-onset schizophrenia-like psychosis significantly improved Positive and Negative Syndrome Scale, Brief Psychiatric Rating Scale, and Clinical Global Impressions scores without impairing cognitive function or aggravating extrapyramidal symptoms 20. Twenty-two patients with schizophrenia who had neuroleptic-induced tardive dyskinesia were given YKS for 12 weeks in an open-label study 17.…”

Section: Controlled Human Studiesmentioning

confidence: 95%

“…One good example of Ibyodochi is YKS, a single prescription that is reported to be effective in treating many different diseases such as dementia,1–14 sleep disorders,15,16 tardive dyskinesia,17 borderline personality disorder,18 and schizophrenia-related diseases 19,20. On the other hand, different herbal formulas may also be used to treat the same disease (called “Dobyoichi” in Kampo).…”

Section: Kampo Medicinementioning

confidence: 99%

“…An open-label study reported the efficacy of YKS on visual hallucinations due to vision loss in patients with Charles Bonnet syndrome in 2011 33. Three reports have suggested the potential for use in persons with schizophrenia-related diseases 17,19,20. Four weeks of adjunctive therapy with YKS for treatment-resistant schizophrenia has been found to decrease Positive and Negative Syndrome Scale scores on the schizophrenia subscale without changing Drug-Induced Extrapyramidal Symptom Scale total scores 19.…”

Section: Controlled Human Studiesmentioning

confidence: 99%

“…YKS has attracted attention in the field of psychiatry due to reports of its efficacy in patients with dementia 1–14. In addition, therapeutic effects of YKS have been reported in the treatment of sleep disorders,15,16 tardive dyskinesia,17 borderline personality disorder,18 and schizophrenia-related diseases 19,20. The claim of YKS’s effectiveness for such a wide variety of indications may produce skepticism toward Kampo medicine and possibly weaken its reputation, especially if YKS is ineffective or harmful because of improper usage.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Yokukan-san: a review of the evidence for use of this Kampo herbal formula in dementia and psychiatric conditions

Okamoto¹,

Iyo²,

Ueda³

et al. 2014

NDT

View full text Add to dashboard Cite

Japanese traditional herbal medicine (Kampo) has its origins in traditional Chinese medicine (TCM). It was introduced to Japan in the middle of the sixth century and has evolved over the past 1,400 years after combining with Japan’s original folk remedies. While it retains some similarities to TCM, Kampo has evolved in Japan, resulting in a system of medicine that has many differences from TCM. Kampo medicine is considered to be very safe; in Japan, Kampo herbal formulas are manufactured by licensed pharmaceutical companies, prescribed by Western-trained medical doctors (usually as a freeze-dried extract), and have quality control standards similar to those of prescription drugs. The present study examined Yokukan-san (Yi-Gan San in TCM), a Kampo formula that has been used empirically in Japan for more than 400 years. Accumulating clinical trials have demonstrated Yokukan-san’s efficacy in treating patients with behavioral and psychological symptoms of dementia, which has resulted in the Japanese Society of Neurology listing it in the Japanese Guidelines for the Management of Dementia 2010. Efficacy in other diseases and conditions, such as sleep disorders, tardive dyskinesia, aggression, and impulsivity has also been reported. This article reviews both clinical and basic studies of Yokukan-san, with the goal of clarifying its clinical indications.

show abstract

Section: Controlled Human Studiesmentioning

confidence: 95%

Section: Kampo Medicinementioning

confidence: 99%

Section: Controlled Human Studiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Yokukan-san: a review of the evidence for use of this Kampo herbal formula in dementia and psychiatric conditions

Okamoto¹,

Iyo²,

Ueda³

et al. 2014

NDT

View full text Add to dashboard Cite

show abstract

“…Recently, a more naturalistic 4-week, open-label study of yokukansan monotherapy for very-late-onset schizophrenia was conducted 38. Considerable improvement of psychotic symptomatology was noticed in all 40 patients.…”

Section: Yokukansanmentioning

confidence: 99%

Yokukansan and its ingredients as possible treatment options for schizophrenia

Ishii

et al. 2014

NDT

View full text Add to dashboard Cite

Schizophrenia is a debilitating psychotic mental disorder that affects almost the entire range of human mental function. The devastating effect of the illness is usually long-lasting and requires lifelong treatment. Despite an evolved psychopharmacological understanding, the overall therapeutic effect of antipsychotics is still not satisfactory. The choice of proper medication presents a clinical dilemma between efficacy and safety. As a result, searching for comparable treatment options with safer profiles is very important. Yokukansan (TJ-54), also called yi-gan san in Chinese, is a traditional herbal medicine with evident therapeutic effect for neuropsychiatric disorders. There are several open-label clinical studies upholding the possibility of using yokukansan to treat schizophrenia or schizophrenia-like psychosis. Evidence from animal studies and neurobiology also sheds light on the antipsychotic implications of yokukansan and its ingredients. Nevertheless, correlations between the experimental environment and clinical settings may be complicated by a number of confounders. Clinical trials with more sophisticated designs are required to fill the gap between the experimental environment and clinical settings.

show abstract

A multicenter, double‐blind, randomized, controlled study of patients with treatment‐resistant schizophrenia treated with yokukansan for 12 weeks

Horiguchi,

Wake,

Murotani

et al. 2023

PCN Reports

Self Cite

View full text Add to dashboard Cite

AimWe conducted a 12‐week double‐blind, placebo‐controlled, multicenter study to evaluate the efficacy and safety of yokukansan in patients with schizophrenia.MethodsPatients with schizophrenia resistant to antipsychotics whose Positive and Negative Syndrome Scale (PANSS) scores were stable within five points were enrolled and assigned to the yokukansan or placebo group. Fifty‐three of the 61 consenting patients were allocated to the yokukansan (n = 27) and placebo (n = 26) groups.ResultsThe changes in total and positive PANSS scores at 12 weeks were significantly greater in the yokukansan group than in the placebo group. There were no significant changes in other psychiatric symptom rating scores in either group. Adverse reactions were reported in six of 27 patients (22.2%) in the yokukansan group and five of 26 patients (19.2%) in the placebo group, all of which were nonserious.ConclusionYokukansan is very safe and has clinical potential as a treatment for schizophrenia in combination with Western medicine.

show abstract

Yokukansan (TJ-54) for treatment of very-late-onset schizophrenia-like psychosis: An open-label study

Cited by 18 publications

References 33 publications

Yokukan-san: a review of the evidence for use of this Kampo herbal formula in dementia and psychiatric conditions

Yokukan-san: a review of the evidence for use of this Kampo herbal formula in dementia and psychiatric conditions

Yokukansan and its ingredients as possible treatment options for schizophrenia

A multicenter, double‐blind, randomized, controlled study of patients with treatment‐resistant schizophrenia treated with yokukansan for 12 weeks

Contact Info

Product

Resources

About